166 related articles for article (PubMed ID: 31028209)
21. Cisplatin plus paclitaxel chemotherapy with or without bevacizumab in postmenopausal women with previously untreated advanced cervical cancer: a retrospective study.
Chu G; Liu X; Yu W; Chen M; Dong L
BMC Cancer; 2021 Feb; 21(1):133. PubMed ID: 33549065
[TBL] [Abstract][Full Text] [Related]
22. Phase II trial of paclitaxel, carboplatin, and bevacizumab for advanced or recurrent cervical cancer.
Suzuki K; Nagao S; Shibutani T; Yamamoto K; Jimi T; Yano H; Kitai M; Shiozaki T; Matsuoka K; Yamaguchi S
Gynecol Oncol; 2019 Sep; 154(3):554-557. PubMed ID: 31285082
[TBL] [Abstract][Full Text] [Related]
23. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240).
Penson RT; Huang HQ; Wenzel LB; Monk BJ; Stockman S; Long HJ; Ramondetta LM; Landrum LM; Oaknin A; Reid TJ; Leitao MM; Method M; Michael H; Tewari KS
Lancet Oncol; 2015 Mar; 16(3):301-11. PubMed ID: 25638326
[TBL] [Abstract][Full Text] [Related]
24. A multicenter real-world study of bevacizumab in heavily pretreated malignant gliomas: clinical benefit is a plausible end point?
Villani V; Fabi A; Tanzilli A; Pasqualetti F; Lombardi G; Vidiri A; Gonnelli A; Molinari A; Cantarella M; Bellu L; Terrenato I; Carosi M; Maschio M; Telera SM; Carapella CM; Cognetti F; Paiar F; Zagonel V; Pace A
Future Oncol; 2019 May; 15(15):1717-1727. PubMed ID: 30977687
[No Abstract] [Full Text] [Related]
25. Nivolumab in chemotherapy-resistant cervical cancer: report of a vulvitis as a novel immune-related adverse event and molecular analysis of a persistent complete response.
Baettig F; Vlajnic T; Vetter M; Glatz K; Hench J; Frank S; Bihl M; Lopez R; Dobbie M; Heinzelmann-Schwarz V; Montavon C
J Immunother Cancer; 2019 Oct; 7(1):281. PubMed ID: 31672171
[TBL] [Abstract][Full Text] [Related]
26. Real-world efficacy and safety of bevacizumab single-maintenance therapy following platinum-paclitaxel chemotherapy plus bevacizumab in patients with advanced cervical cancer.
Kotaka S; Kondo E; Kawai Y; Okamoto K; Kishigami Y; Yamawaki T; Nagao K; Hirata T; Suzuki S
J Gynecol Oncol; 2023 Sep; 34(5):e60. PubMed ID: 37170726
[TBL] [Abstract][Full Text] [Related]
27. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
Coleman RL; Brady MF; Herzog TJ; Sabbatini P; Armstrong DK; Walker JL; Kim BG; Fujiwara K; Tewari KS; O'Malley DM; Davidson SA; Rubin SC; DiSilvestro P; Basen-Engquist K; Huang H; Chan JK; Spirtos NM; Ashfaq R; Mannel RS
Lancet Oncol; 2017 Jun; 18(6):779-791. PubMed ID: 28438473
[TBL] [Abstract][Full Text] [Related]
28. [Progress on clinical application of bevacizumab for the treatment of refractory cervical cancer].
He B; Chai Y; Wang T; Zhou Z; Liu Z
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2016 May; 45(4):395-402. PubMed ID: 27868413
[TBL] [Abstract][Full Text] [Related]
29. A randomized phase II/III trial of conventional paclitaxel and carboplatin with or without bevacizumab vs dose-dense paclitaxel and carboplatin with or without bevacizumab, in stage IVB, recurrent or persistent cervical carcinoma: Japan Clinical Oncology Group Study (JCOG1311).
Ishikawa M; Nakamura K; Shibata T; Tanaka K; Kitagawa R; Kobayashi H; Yaegashi N;
Jpn J Clin Oncol; 2018 Dec; 48(12):1096-1100. PubMed ID: 30295796
[TBL] [Abstract][Full Text] [Related]
30. Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial.
Romera A; Peredpaya S; Shparyk Y; Bondarenko I; Mendonça Bariani G; Abdalla KC; Roca E; Franke F; Melo Cruz F; Ramesh A; Ostwal V; Shah P; Rahuman SA; Paravisini A; Huerga C; Del Campo García A; Millán S
Lancet Gastroenterol Hepatol; 2018 Dec; 3(12):845-855. PubMed ID: 30262136
[TBL] [Abstract][Full Text] [Related]
31. Prognostic impact of adding bevacizumab to carboplatin and paclitaxel for recurrent, persistent, or metastatic cervical cancer.
Yasunaga M; Yahata H; Okugawa K; Shimokawa M; Maeda Y; Hori E; Kodama K; Yagi H; Ohgami T; Onoyama I; Asanoma K; Kato K
Taiwan J Obstet Gynecol; 2022 Sep; 61(5):818-822. PubMed ID: 36088050
[TBL] [Abstract][Full Text] [Related]
32. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial.
Zielinski C; Láng I; Inbar M; Kahán Z; Greil R; Beslija S; Stemmer SM; Zvirbule Z; Steger GG; Melichar B; Pienkowski T; Sirbu D; Petruzelka L; Eniu A; Nisenbaum B; Dank M; Anghel R; Messinger D; Brodowicz T;
Lancet Oncol; 2016 Sep; 17(9):1230-9. PubMed ID: 27501767
[TBL] [Abstract][Full Text] [Related]
33. Post-bevacizumab Clinical Outcomes and the Impact of Early Discontinuation of Bevacizumab in Patients with Recurrent Malignant Glioma.
Cha Y; Kim YJ; Lee SH; Kim TM; Choi SH; Kim DW; Park CK; Kim IH; Kim JH; Kim E; Choi B; Kim CY; Kim IA; Heo DS
Cancer Res Treat; 2017 Jan; 49(1):129-140. PubMed ID: 27188199
[TBL] [Abstract][Full Text] [Related]
34. Continuous Administration of Bevacizumab After Disease Progression in Recurrent Ovarian Cancer: A Retrospective Observational Study.
Tanigawa T; Matoda M; Omi M; Aoki Y; Netsu S; Nomura H; Okamoto S; Omatsu K; Yunokawa M; Kanao H; Takeshima N
Anticancer Res; 2020 Sep; 40(9):5285-5290. PubMed ID: 32878818
[TBL] [Abstract][Full Text] [Related]
35. New schedule of bevacizumab/paclitaxel as first-line therapy for metastatic HER2-negative breast cancer in a real-life setting.
Cannita K; Paradisi S; Cocciolone V; Bafile A; Rinaldi L; Irelli A; Lanfiuti Baldi P; Zugaro L; Manetta R; Alesse E; Ricevuto E; Ficorella C
Cancer Med; 2016 Sep; 5(9):2232-9. PubMed ID: 27416882
[TBL] [Abstract][Full Text] [Related]
36. Feasibility study on combination chemotherapy using nogitecan hydrochloride (topotecan) and cisplatin for patients with metastatic, persistent, or recurrent uterine cervical cancer.
Shimada M; Sato S; Oishi T; Itamochi H; Kigawa J; Takeshima N; Aoki D; Aoki Y; Nambu Y; Ochiai K
Int J Clin Oncol; 2016 Oct; 21(5):969-974. PubMed ID: 27142771
[TBL] [Abstract][Full Text] [Related]
37. Response to Combination Chemotherapy With Paclitaxel/Ifosfamide/Platinum Versus Paclitaxel/Platinum for Patients With Metastatic, Recurrent, or Persistent Carcinoma of the Uterine Cervix: A Retrospective Analysis.
Choi HJ; Paik ES; Choi CH; Kim TJ; Lee YY; Lee JW; Bae DS; Kim BG
Int J Gynecol Cancer; 2018 Sep; 28(7):1333-1341. PubMed ID: 30045137
[TBL] [Abstract][Full Text] [Related]
38. [Analysis of prognostic factors and therapeutic patterns of recurrent stage Ⅰb-Ⅱa cervical squamous carcinoma treated with radical hysterectomy].
Ou ZJ; Zhao D; An JS; Sun CY; Huang MN; Li B; Wu LY
Zhonghua Fu Chan Ke Za Zhi; 2019 Jun; 54(6):399-405. PubMed ID: 31262124
[No Abstract] [Full Text] [Related]
39. A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109).
Hattori Y; Satouchi M; Shimada T; Urata Y; Yoneda T; Mori M; Nishimura T; Sunadome H; Kumagai T; Imamura F; Fujita S; Kaji R; Hata A; Tachihara M; Morita S; Negoro S
Lung Cancer; 2015 Feb; 87(2):136-40. PubMed ID: 25553650
[TBL] [Abstract][Full Text] [Related]
40. Platinum sensitivity and non-cross-resistance of cisplatin analogue with cisplatin in recurrent cervical cancer.
Takekuma M; Kuji S; Tanaka A; Takahashi N; Abe M; Hirashima Y
J Gynecol Oncol; 2015 Jul; 26(3):185-92. PubMed ID: 26197856
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
